The FDA has made amendments to conditions of authorization for some SARS-CoV-2 tests with emergency use authorization. Test makers must provide updated authorized labeling to the FDA within three months as a supplement to the EUA, and they must evaluate their tests' performance on viral mutations.
Designed specifically for the transfusion medicine and cellular therapy community, AABB SmartBrief is a FREE, daily e-mail newsletter. It provides a summary of the most important news in our field to members of AABB and beyond. To save time and stay smart, sign up today to receive AABB SmartBrief, free of charge.